KRT5 and breast cancer: Initial clues suggesting BC heterogeneity came from studies showing that they could differ in their ability to retain label in bromodeoxyuridine (BrdU) incorporation assays, and exhibit distinct clonogenic behavior due to different ability to activate the Krt5 promoter (Borthwick et al., 2001; Schoch et al., 2004).